MX2019001979A - Agonista de ppar? para el tratamiento de neoplasias hematicas. - Google Patents

Agonista de ppar? para el tratamiento de neoplasias hematicas.

Info

Publication number
MX2019001979A
MX2019001979A MX2019001979A MX2019001979A MX2019001979A MX 2019001979 A MX2019001979 A MX 2019001979A MX 2019001979 A MX2019001979 A MX 2019001979A MX 2019001979 A MX2019001979 A MX 2019001979A MX 2019001979 A MX2019001979 A MX 2019001979A
Authority
MX
Mexico
Prior art keywords
treatment
blood cancers
ppary agonist
ppary
agonist
Prior art date
Application number
MX2019001979A
Other languages
English (en)
Spanish (es)
Inventor
Mantzoros Christos
Original Assignee
Intekrin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intekrin Therapeutics Inc filed Critical Intekrin Therapeutics Inc
Publication of MX2019001979A publication Critical patent/MX2019001979A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019001979A 2016-08-18 2017-08-18 Agonista de ppar? para el tratamiento de neoplasias hematicas. MX2019001979A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662376749P 2016-08-18 2016-08-18
PCT/US2017/047578 WO2018035446A1 (en) 2016-08-18 2017-08-18 PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS

Publications (1)

Publication Number Publication Date
MX2019001979A true MX2019001979A (es) 2019-09-19

Family

ID=61197183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001979A MX2019001979A (es) 2016-08-18 2017-08-18 Agonista de ppar? para el tratamiento de neoplasias hematicas.

Country Status (12)

Country Link
US (1) US20210379049A1 (https=)
EP (1) EP3500268A4 (https=)
JP (2) JP2019524888A (https=)
KR (1) KR20190064573A (https=)
CN (1) CN110461329A (https=)
AU (1) AU2017313839A1 (https=)
BR (1) BR112019003130A2 (https=)
CA (1) CA3034258A1 (https=)
EA (1) EA201990512A1 (https=)
MX (1) MX2019001979A (https=)
SG (2) SG11201901320WA (https=)
WO (1) WO2018035446A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
WO2020243058A1 (en) * 2019-05-30 2020-12-03 Coherus Biosciences, Inc. Compositions and methods to treat cancer
JP2022104747A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗ウイルス剤
JP2022104746A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗がん剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3018186B1 (ja) * 1999-03-09 2000-03-13 大阪大学長 抗炎症剤、単球系細胞の増殖抑制剤
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
JP2010265216A (ja) * 2009-05-14 2010-11-25 Takeda Chem Ind Ltd 複素環化合物
KR102056756B1 (ko) * 2013-01-30 2019-12-17 인테크린 테라퓨틱스, 아이엔씨. 다발성 경화증의 치료를 위한 PPARγ 작용제
ES2866883T3 (es) * 2016-06-08 2021-10-20 Support Venture Gmbh Combinaciones farmacéuticas para el tratamiento del cáncer

Also Published As

Publication number Publication date
EP3500268A4 (en) 2020-04-15
EA201990512A1 (ru) 2019-08-30
CA3034258A1 (en) 2018-02-22
JP2019524888A (ja) 2019-09-05
KR20190064573A (ko) 2019-06-10
AU2017313839A1 (en) 2019-03-07
BR112019003130A2 (pt) 2019-05-21
CN110461329A (zh) 2019-11-15
US20210379049A1 (en) 2021-12-09
SG10202101501PA (en) 2021-03-30
JP2022116304A (ja) 2022-08-09
SG11201901320WA (en) 2019-03-28
WO2018035446A1 (en) 2018-02-22
EP3500268A1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
ZA202307128B (en) Anti-cd38 antibodies for treatment of acute myeloid leukemia
DK3140319T3 (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MX2021015102A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
EP3800248A3 (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
GEP20186933B (en) Substituted dihydroisoquinoline compounds
TN2019000211A1 (en) Antitumoral compounds
PH12015502248A1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
PH12017501879A1 (en) Methods for treating cancer
MX2019001979A (es) Agonista de ppar? para el tratamiento de neoplasias hematicas.
MX366765B (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
MX2017013359A (es) Métodos para tratar el cáncer.
IL248203A0 (en) Innovative immunotherapy against blood tumors such as acute leukemia in the spinal cord
EA201992557A1 (ru) Противоопухолевые соединения
UA90817U (uk) Сполука 1,1-діетилкарбокси-2-трифторметил-2-(5'-бромуридил-1'-)етилен з потенційними фізіологічними властивостями